To understand the importance of the link between male infertility and CaP, some background is necessary. CaP is the most common malignancy diagnosed in men and the second most common cause of cancer related Purpose of review Male infertility impacts a substantial proportion of men and has serious implication for a man's quality of life. Advances in reproductive technology may allow men to bypass urologic care in order to achieve their family planning goals. Recent data suggests that male reproductive failure may be a harbinger of future urologic diseases, including prostate cancer (CaP), thus emphasizing the importance of dedicated urologic evaluation and care for all male infertility patients.
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Male infertility
Infertility is defined as the failure to conceive despite 1 year of regular, unprotected intercourse. Approximately 15% of couples overall will experience infertility and this prevalence rises with advancing age. Of these couples, 20% will have a male factor that is solely responsible and male factors will contribute to an additional 30% of cases [1,2 ,3].
With the advent of assisted reproductive technologies (ART) pregnancy may be achieved in some cases without urologic expertise; however, clinically significant medical disease that underlies male infertility may be missed [4] [5] [6] . In a landmark study, Honig et al.
[3] studied more than 1000 infertile men and identified diseases that required intervention, including cancer, in 10 cases (0.8%). Similarly, Kolettis and Sabanegh [7] evaluated 536 infertile men and identified 33 (6%) with medical diseases, including cases of both prostate and testicular cancer [8] . These findings initiated a new era of research focused on understanding the association between male infertility and malignancy.
It is now accepted that male reproductive failure may precede testicular germ cell cancer by up to a decade and new insights regarding the association between male infertility and other oncologic disease have materialized [2 ,9 ] . Given common disease pathways, recent attention has been placed on the association between male infertility and prostate cancer (CaP). The remainder of this review will focus on the epidemiologic data that links these diseases, the limitations in the data, and the potential biologic mechanisms that may underlie their association. mortality in the USA; however, its cause remains poorly understood [10, 11] . The most agreed upon risk factors remain age, family history, and race [12] .
The impact of race on CaP risk has been thoroughly investigated. Studies have demonstrated a relatively lower risk in Asia and higher risk in North American and Scandanavian countries. Interestingly, after emigration to Western society, the protective effect conferred to men of Asian descent appears to be partially lost within a generation, suggesting a cultural difference in exposures that predisposes a man to develop CaP. Regardless of race, a positive family history has been found to consistently confer a higher risk of CaP [13] .
Because of persistent limitations in our understanding of the risks for CaP, new efforts have been made to explore novel factors that increase risk for this ubiquitous disease. These risk factors include genetic variation, prostate infection and inflammation, androgen and androgen receptor variants, nutrition, and reproductive health [11, 12, [14] [15] [16] [17] [18] [19] [20] .
Epidemiologic data linking male reproductive health and prostate cancer
Each of the following subsections will explore different measures of male reproductive health and CaP risk. Table 1 provides a summary of the studies of association between paternity and CaP. These studies were designed to explore theories that androgen sensitivity is common to both CaP and fertility [21] . In 2002, Dennis and Dawson [22] consolidated multiple studies of paternity and CaP. The primary risk factor of interest was prior sexually transmitted infections; however, this meta-analysis of 18 studies did not identify a statistically significant association between the number of offspring and CaP. Giwercman et al. [23] provided evidence from a cohort study of 48 850 Swedish men that childless men were 20% less likely to develop CaP compared with men with children [odds ratio (OR) 0.83, 95% confidence interval (CI) 0.81-0.86]. A smaller study by Negri et al.
Fatherhood and prostate cancer risk
[24] of 1249 Italian men found no association between men with fewer or no children and CaP, but highlighted the importance of controlling for key social factors such as marital status. In a variation of this type of investigation, Harlap et al. [25 ] found that men with a history of fathering stillborn offspring were at higher risk of developing CaP.
Given these conflicting results, Jorgensen et al. [21] performed the largest population-based cohort study and reported on 51.6 million person-years of follow up among Danish men. In this study, 3400 cases of CaP were identified and childless men had a 16% relative reduction in CaP diagnoses [relative risk (RR) 0.84, 95% CI 0.90-1.08], consistent with the findings of Giwercman et al. [23] . Interestingly, the authors found that among fathers, CaP risk was highest among those with the fewest children in a dose-response relationship, whereby with each additional child, CaP risk further decreased ( Fig. 1 ) [21] .
Most recently, Eisenberg et al. [26] evaluated the relationship between offspring number and CaP risk among 161 823 men enrolled in the National Institutes of Health -American Association of Retired Persons Diet and Health Study. The study identified 8134 cases of CaP and found that overall there was no relationship between fatherhood and incident CaP [hazard ratio (HR) 0.94, 95% CI 0.86-1.02]. However, after stratifying for CaP screening, prostate-specific antigen (PSA) unscreened childless men had a lower risk of CaP (HR 0.73, 95% CI 0.58-0.91) compared with fathers.
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Key points
The sensitivity of male gametes may make infertility a harbinger of other medical diseases, including CaP. Epidemiologic data relating male reproductive events to CaP risk is mixed but provides strong impetus for additional research. Current advances in molecular genetics and epigenetics may allow a deeper understanding of the mechanisms driving these linkages and ultimately lead to new interventions and predictive models for assessing CaP risk. Offspring gender and prostate cancer risk Table 2 summarizes the studies of association between offspring gender and CaP. Investigators first reported on the association or lack of association between offspring gender and CaP in the 1980s with mixed results [27] [28] [29] .
Since that time, the deletion of Y-chromosome specific genes have been implicated in the development of CaP and in addition to their requirement for male sex determination, Y-chromosome specific genes are a known cause of impaired spermatogenesis [30] . Harlap et al. [31] hypothesized that a Y chromosome locus might be a common cause for failure to father sons and CaP. The authors utilized the Jewish Perinatal Cohort Study of 38 934 men and found that an absence of male offspring conferred a 40% increased risk (RR 1.40, 95% CI 1.04-1.91) for CaP. Following a dose-response relationship, the fewer sons a man sired as a proportion of his total offspring, the higher his risk of cancer. Among all men who developed CaP, mortality was highest among men who did not father sons, suggesting some degree of association with more aggressive cancers. In an effort to replicate these data, Bermejo et al. [32] reported on more than 3.1 million men of whom 120 812 developed prostate. In this much larger study, the authors failed to find an association between offspring gender and CaP risk. Others have reported similar negative findings [33] .
Eisenberg et al. [26] reported the association between offspring gender and CaP in their study of US men. Among men unscreened for CaP with PSA, the inability to father daughters appeared to confer a weak but statistically significant increased risk for CaP.
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The results of studies of paternity and gender offspring have been inconsistent. Each of these studies relied upon a surrogate marker for male fertility, namely number or gender of offspring in the absence of a specific fertility evaluation. A man's ability to father children is intimately related to the fertility potential of his partner, his socioeconomic status, and his personal choices and thus the number of children fathered may not accurately reflect a man's biologic fertility. Our group recently studied a US-based cohort of men evaluated specifically for infertility and found an association between male factor infertility and CaP [9 ] . We identified 22 562 men evaluated for infertility in California and determined their subsequent risk of CaP by linking them to the state-wide cancer registries after a median follow-up time of 11 years. Overall, men evaluated for infertility but not necessarily with male factors, did not have increased risk of cancer relative to the general population [standardized incidence ratio (SIR) 0.9; 95% CI 0.8, 1.1]. When cancer was stratified by grade, risk was significantly higher for men with male factor infertility who developed high grade CaPs (SIR 2.0; 95% CI 1.2, 3.0). In multivariate analyses, men with male factor infertility were not statistically significantly more likely to be diagnosed with low grade CaP compared with those without (HR 1.5, 95% CI 1.0, 2.3); however, they were nearly three times more likely to be diagnosed with high grade CaP (HR 2.8, 95% CI 1.5, 5.0). These data suggest that male factor infertility may be an early and identifiable risk factor for clinically significant CaP. Further, the difference in risk between low grade and high grade cancers suggests that CaP screening alone does not account for the increased cancer risk. This apparent increased risk for high 508 Andrology, sexual dysfunction and infertility grade CaP may offer some insight into findings from the Jerusalem Perinatal Cohort study: the higher mortality seen in men with CaP who did not father sons.
Mechanisms that may underlie the association between male reproductive health and prostate cancer
Male infertility may be a harbinger of future cancers. From puberty onward, spermatogenesis requires rapid and organized cell division that is exquisitely sensitive to a variety of genetic, hormonal, and environmental insults [34] . These same insults may place individuals at higher risk for the development of cancer. Because germ cell renewal and meiosis rapidly accelerates at a very young age, declines in spermatogenesis or abnormal sperm quality may be the first marker of insult, long before cancer is detected [35] . This section provides a brief survey of potential causes of the link between poor sperm quality and subsequent CaP. To date, some of these causes remain hypothetical but provide a foundation for future research.
Androgen levels and androgen receptor sensitivity
Several lines of evidence support an association among androgen production, androgen sensitivity, male reproduction, and CaP.
Testicular dysgenesis syndrome
Multiple Danish studies have culminated in the testicular dysgenesis syndrome (TDS) [36] [37] [38] . TDS theory relates environmental modulators, genetics, hormonal function, and infertility in the development of testis cancer [38] . Because of the androgen sensitivity of the prostate gland, this theory has applicability to CaP. TDS theory posits that certain male reproductive disorders such as cryptorchidism, hypospadias, infertility, and testicular germ cell tumor may be manifestations of a fundamental perturbation of gonadal development related to environmental toxin exposure and underlying genetic predisposition [39] . Because of abnormal gonadal function, androgen sensitive organs such as the prostate may not receive adequate differentiating signals during critical stages of development thereby increasing their risk for malignancy [40] [41] [42] .
Androgen receptor CAG repeats
Variations in the number of CAG repeats within the gene that codes for the androgen receptor have been described in association with both male infertility and CaP. Mosaad and colleagues assessed androgen receptor CAG repeat expansion in Egyptian men evaluated for infertility and found differences between infertile and control groups. The authors reported a negative correlation between CAG repeat length and sperm count thereby validating the concept that long stretches of CAG repeat may be associated with derangement of sperm production, presumably via decreased androgen receptor function [43] [44] [45] [46] [47] . Data associating androgen receptor CAG repeats with CaP have been inconsistent but several studies have linked variation in CAG repeat length to clinically aggressive CaP [48] [49] [50] [51] [52] .
Prostasomes
Prostasomes are small membrane-bound vesicles produced within prostate acini that fuse with and transfer proteins to sperm whereby they modulate sperm motility and function. In the presence of prostasomes, sperm motility is increased, premature acrosome reactions are prevented and sperm integrity is preserved during transit through the female reproductive tract, thus they likely play a key role in male fertility [53] . Prostasomes also have been proposed as an etiologic factor in CaP. The mechanism by which they contribute to malignant transformation is unclear; however, potential mechanisms include the promotion of tumor angiogenesis, cell cycle dysregulation, and immunoprotection of malignantly transformed cells [54] .
DNA mismatch repair
The mismatch repair system is a DNA repair mechanism that corrects mispaired bases during DNA replication errors. Cancer cells deficient in mismatch repair proteins have a 10 2 to 10 3 -fold increase in the mutation rate.
Defective DNA repair has previously been described in association with particular cancers, namely nonpolyposis colon cancer, retinoblastoma, and melanoma, and is suspected to play a role in certain gastric, breast cancer and ovarian cancer [35, 43, [55] [56] [57] . Work by Suter et al. [35] found that epimutations of the DNA mismatch repair gene MLH1 may be present in both somatic and germ cells among select men with nonpolyposis colorectal cancer.
Data from studies of mice suggest that mutations in genes needed for DNA repair (PMS2, Mlh1) also lead to infertility characterized by meiotic arrest, a phenomenon that also has been observed in infertile men with azoospermia [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] . To date, soma-wide mutations of DNA mismatch repair genes have not been described in this population of men. More recently, similar genetic aberrations have been described for CaP, whereby polymorphisms of the mismatch repair gene MSH3 and elevated levels of the mismatch repair protein PSM2 and have been associated with CaP and with biochemical recurrence of CaP after radical prostatectomy [68, 69] . Thus transcriptional mismatch repair errors in both germ-line DNA and somatic cell DNA could stem from one source and provide a biologic explanation for the link between CaP and male infertility.
Y chromosome
Abnormalities of the Y chromosome have been proposed to underlie the association between infertility and CaP [30, 31, [70] [71] [72] [73] . The deletion of genes from the Y chromosome is one of the most well studied genetic causes of abnormal sperm production in men [74] . Y microdeletions occur in 6-8% of severely oligozoospermic men and in 3-15% of azoospermic men, thus Y microdeletions are the most common molecularly defined cause of male infertility [75] [76] [77] .
Advances in positional cloning studies have identified most of the genes on the human Y chromosome, and have provided a resource for studying the expression of its genes in CaP. Lau and Zhang [78] examined the expression of the Y chromosome genes in a panel of prostate samples from men with benign prostatic hyperplasia, low-grade and/or high-grade carcinoma, and the prostatic cell line, LNCaP, stimulated by androgen treatment. Results from this study revealed heterogeneous and differential expression patterns of the Y chromosome genes that raise the possibility that some of these genes are either involved in or are affected by the oncogenic processes of the prostate. The up-regulation and down-regulation of several Y chromosome genes by androgen suggest that they may play a role(s) in the hormonally stimulated proliferation of CaP cells.
Epigenetic regulation
Epigenetics is the study of changes produced in gene expression caused by mechanisms other than changes in the underlying DNA sequence. Examples of such changes might be DNA methylation or histone deacetylation, both of which serve to suppress gene expression without altering the sequence of the silenced genes. These changes may remain through cell divisions for the remainder of the cell's life and may also last for multiple generations. However, there is no change in the underlying DNA sequence of the organism.
Recent data indicate that epigenetics may link infertility and CaP [79] . Multiple studies have reported the detrimental impact of epimutations on spermatogenesis.
Rajender et al. [80] recently reviewed the available literature and found strong evidence that epigenetic aberrations are associated with poor semen quality and male infertility and may be significantly impacted by environmental factors.
Similar epigenetic mechanisms have been implicated in the development of multiple cancers, including CaP [35, 81, 82] . Aberrant DNA methylation (hypomethylation and hypermethylation) is the best-characterized alteration in CaP and leads to genomic instability and inappropriate gene expression [83] . Global and locus-specific changes in chromatin remodeling are implicated in CaP, with evidence suggesting a causative dysfunction of histone-modifying enzymes. MicroRNA deregulation also contributes to prostate carcinogenesis, including interference with androgen receptor signaling and apoptosis.
Importantly, environmental toxins/drugs may affect fertility and cancer risk via epigenetic modifications and this may account for the simultaneous impact of environment factors on both reproductive health and cancer risk. For example, 5-aza-2 0 -deoxycytidine, an anticancer agent, has been shown to cause a decrease in global DNA methylation that leads to altered sperm morphology, decreased sperm motility, decreased fertilization capacity, and decreased embryo survival. Similarly, endocrine disruptors, such as methoxychlor (an estrogenic pesticide) and vinclozolin (an antiandrogenic fungicide) have been found by experiments on animals to affect epigenetic modifications that may cause spermatogenic defects and poor prostate health in subsequent generations [84] .
Environmental exposures
Although multiple environment toxicants have been implicated as causative factors for both poor spermatogenesis and CaP, perhaps the best-described agents are those that mimic the effects of estrogens, so-called phytoestrogens and xenoestrogens. A significant body of toxicology data suggests that exposure to certain endocrine disrupters is associated with reproductive toxicity, including abnormalities of the male reproductive tract (cryptorchidism, hypospadias), reduced semen quality, and impaired fertility in adults [85] .
Similarly, given the hormonal sensitivity of the prostate gland, there is increasing evidence both from epidemiology studies and animal models that specific endocrinedisrupting compounds may have an impact on CaP risk. These effects may be linked to interference with estrogen signaling and altered estrogen levels within the body. Epidemiologic evidence links specific pesticides, polychlorinated biphenyls, and inorganic arsenic exposures to elevated CaP risk. Animal studies demonstrate augmentation of prostate carcinogenesis with several other environmental estrogenic compounds including cadmium, ultraviolet filters, and bisphenyl A. There is increased sensitivity of the prostate to these endocrine disruptors during development, such that during the in-utero and neonatal period as well as during puberty, individuals are particularly vulnerable [86] . Adult exposure also has impact as Xu et al. [87] recently reported a significant association between serum levels of organochlorine pesticides and prevalent CaP.
Reconciling differences in study findings
The compiled epidemiologic data are heterogeneous and as a result, a clear picture of how a man's reproductive health may predict his risk for cancer has not yet emerged. Differences in the finding of these studies likely arise from multiple sources. The most important difference is in the definition of both the exposure, a male reproductive event, and in the outcome, CaP.
With regard to defining the exposures of interest, the number of children a man has fathered may not, in all cases, be an accurate reflection of his reproductive biology. Although each of these 'reproductive events': paternity, offspring gender, and biologic infertility may be individual predictors of CaP (or protection against a future cancer), the mechanisms through which each predictor is etiologically related to cancer may not be the same. Thus, each of these factors may provide a unique window into the future prostate health of man and should not be discounted.
Disparities in study findings also result from differences in the assessment of outcome, namely, CaP. Data from large observational cohorts of men diagnosed with CaP have identified a subset of men at very low risk for prostate-cancer specific mortality during their lifetime and autopsy studies have described the occurrence of clinically indolent CaP in men dying of other causes [88] [89] [90] . Because of these aspects of CaP, it is feasible that we are dealing with two distinct diseases: low grade CaP which is indolent, and high grade CaP which is potentially life threatening. CaP risk factor studies should be aimed at identifying predictors of high-risk disease, in young men who are most likely to benefit from aggressive therapy. Further, it should be expected that predictors of 'all' CaP, of which 2/3 is low grade, may not be the same as the predictors of isolated high grade cancer.
In spite of these highly varied findings, the association between male reproductive health in a man's fourth decade (30s) and his development of aggressive CaP in his sixth decade (50s) should not be ignored. Rather these findings, combined with the robustness of the potential common underlying mechanisms, should serve as the foundation of future longitudinal studies of male reproductive health that are more specific and directed in their approach to answering questions about the association between male reproductive failure and future systemic disease.
